P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text

Medicine, Hematology, Oncology +17

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Thomas H. Schindler, William G. Bornmann, Patricia Pellicena et al. · Science · 2000 · 1.8K citations

Life Sciences, Medicinal Chemistry, Pharmacology +16

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations

Medicine, Molecular Biology, Oncology +15

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

Nicholas J. Donato, Ji Yuan Wu, Jonathan Stapley et al. · Blood · 2002 · 663 citations · Full text

Medicine, Hematology, Oncology +11